Search Results 1861-1870 of 20071 for Receptor
Chimeric antigen receptor-T cell therapy (CAR-T cell therapy) could provide a revolutionary approach to organ transplantation for patients who are hard to ...
T-cell receptor diversity may be key to treatment of follicular lymphoma, Mayo study finds. Joe Dangor. February 19, 2019.
Learn about the symptoms, causes and treatment of this immune system condition that results in too much thyroid hormone.
Has received chimeric antigen receptor (CAR) or chimeric antigen receptor T-cell (CAR-T) therapy within 90 days of starting TJ011133 OR has received prior ...
Participation eligibility · Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpressing malignancies. · Radiotherapy (except for ...
... receptor, programmed cell death 1 (PD-1), as well as effects on the immune system. The exploratory objectives are to: 1) evaluate biomarkers that may ...
... receptor antibody encephalitis, Progressive multifocal leukoencephalopathy, Autoimmune encephalitis, Meningoencephalitis, Neurosarcoidosis, Myelopathy, Myelitis.
Qin's research group is identifying targets that can be incorporated in the design and subsequent engineering of chimeric antigen receptor (CAR)-T cell ...
Malignant cellular therapies, such as chimeric antigen receptor-T cell therapy. Gene therapy, including genetic engineering and reengineered viruses ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.